Abstract
Introduction and hypothesis
To evaluate the effects of oral anticholinergic (OAC) drugs on tear secretion in women with overactive bladder over a 3-month follow-up period.
Methods
In this prospective study, 108 women with a diagnosis of overactive bladder were evaluated. All patients were examined ophthalmologically at baseline (day 0), and after 1 month (day 30) and 3 months (day 90) of OAC treatment. Tear film break-up time (BUT) and Schirmer 1 test results were recorded. The subjective complaints of the patients including dry mouth, and burning, dryness and foreign body sensation in the eyes, were also recorded. The chi-squared test or the paired sample t test as appropriate, was used for statistical analysis.
Results
The mean age of the patients was 51.8 ± 9.2 years (30 – 69 years). The most frequent subjective complaints were dry mouth and dry eyes and both complaints were significant on both day 30 and day 90. Both tear film BUT and Schirmer 1 test results were significantly lower on day 30 and day 90. Dry eye measurement values worsened with prolongation of OAC treatment (p = 0.037 and p = 0.012 for BUT, and p = 0.046 and p = 0.035 for Schirmer 1 test, on day 30 and day 90, respectively).
Conclusions
OAC treatment in women with overactive bladder significantly and progressively affects tear secretion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gani J, Perlis N, Radomski SB (2012) Urologic medications and ophthalmologic side effects: a review. Can Urol Assoc J 6:53–58
Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3:335–348
Cetinel B, Onal B (2013) Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol 54:806–815
Chapple CR, Nilvebrant L (2002) Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs R D 3:75–81
Lachkar Y, Bouassida W (2007) Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 18:129–133
Abrams P, Andersson KE, Buccafusco JJ, Chapple C, Chet de Groat W, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578
Lemp MA (2008) Advances in understanding and managing dry eye disease. Am J Ophthalmol 146:350–356
Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M (2007) Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol 14:595–597
Eskandar OS, Eckford SD, Whittaker KW (2005) Treatment of overactive bladder (OBA) with anti-cholinergic drugs and the risk of glaucoma. J Obstet Gynaecol 25:419–421
Yaycioglu RA, Yaycioglu O, Akova YA, Guvel S, Ozkardeş H (2005) Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 59:588–592
Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U (2014) The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J 25:1479–1482
Yayla EM, Yavuz E, Bilge U, Keskin A, Binen E (2015) Drugs with anticholinergic side-effects in primary care. Niger J Clin Pract 18(1):18–21
Wong J, Lan W, Ong LM, Tong L (2011) Non-hormonal systemic medications and dry eye. Ocul Surf 9:212–226
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None
Conflicts of interest
None
Rights and permissions
About this article
Cite this article
Ozen Tunay, Z., Ozdemir, O., Ergintürk Acar, D. et al. Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence. Int Urogynecol J 27, 919–922 (2016). https://doi.org/10.1007/s00192-015-2911-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-015-2911-6